DelNova is a company that provides therapeutics using clinically validated molecules. It develops ReViVox, a drug candidate addressing complications caused by off-target muscle paralysis following aesthetic and medical neurotoxin therapies, specifically botulinum-Type A toxins. The company aims to improve the outcomes of neurotoxin therapies in aesthetic and overactive bladder.